Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

May

Today In Oncology

Glecirasib Shows Efficacy and Safety in KRAS G12C–Mutated NSCLC

Metastatic Castration-Resistant Prostate Cancer Addition of LuPSMA to Enzalutamide

Breast Implant–Related Cancers: Should Our Patients Be Concerned?

Pediatric AML Comparison of Induction Regimens

Older Patients With Newly Diagnosed Hodgkin Lymphoma Preexisting Heart Failure and Survival Outcomes